Archive for the ‘cancer’ Category

University Hospitals Case Medical Center Remains Among the Elite in U.S. News & World Report Annual Survey

July 16, 2010

University Hospitals Case Medical Center (UHCMC) has again ranked among the elite in the latest U.S. News & World Report hospital rankings.  In this year’s survey, UHCMC ranked seven clinical specialties in the top 50 for hospitals and health systems nationwide.

Top among clinical departments at UHCMC, the Department of Medicine again contributed four of the specialties – Gastroenterology (28), Geriatrics (28), Cancer (34), and Pulmonology (42). This contribution by the Department of Medicine figured significantly into UHCMC joining only 152 other hospitals, or the top 3% of the nation’s 5,000 eligible healthcare organizations.

“This consistent level of excellence in compassionate, cost-effective patient care is a testament to the quality and dedication of the full time faculty in the Department of Medicine and to the leadership of our organizations.”

Richard A. Walsh, MD, Chairman, Department of Medicine

Angiotensin-Receptor Blockades (ARBs) Found to Raise Risk of Cancer

July 9, 2010

Dr. Daniel Simon M.D., Division Chief of Cardiovascular Medicine and Director of HM-Heart and Vascular Institute at UHCMC; Dr. James Fang M.D., Section Chief of Heart Failure and Medical Director of Heart Transplantation at UHCMC; IIke Sipahi M.D., Associate Director of Heart Failure & Transplantation at UHCMC at the Harrington-McLaughlin Heart & Vascular Institute of UHCMC researched the effects of Angiotensin-Receptor Blockers (ARBs) on the risk of cancer.

ARBs are a widely utilized drug class used for treatment of hypertension, heart failure, diabetic nephropathy, and recently, for cardiovascular risk reduction.

Randomized controlled trials of ARBs with a follow-up of at least 1 year, and enrolling at least 100 patients were included in this meta-analysis. Information on new cancer development (first diagnosis) was available for 61,590 patients from five trials. Cancer data on common types of solid organ cancers such as lung and prostate cancer were available for 68,402 patients from five trials, and data on cancer deaths were available for 93,515 patients from eight trials.

The meta-analysis showed that patients randomly assigned to receive ARBs had a significantly increased risk of new cancer occurrence compared with patients in control groups (7.2%vs 6.0%). Specifically, the risk of lung cancer was increased by 25%, which was also statistically significant.

“We have found the risk of new cancers was increased with these medications by 8-11 percent.  Most importantly, risk of lung cancer was increased by 25 percent,” said Dr. Sipahi. Although there was no statistically significant excess in cancer deaths (1.8% with ARBs vs 1.6% with control) the investigators pointed out that the average duration of follow-up of 4 years may be too short to capture cancer deaths.

“In medicine, physicians must balance the benefits and risks of all drug and device therapies.  We recommend that patients discuss the findings of this study with their physicians since ARBs are effective agents in the treatment of high blood pressure and heart failure,” said Dr. Simon.

They conclude that because of the limited data, it is not possible to draw conclusions about the exact risk of cancer associated with each individual ARB on the market, but they stated that their findings need further investigation.

In response to this publication from Case Western Reserve University, the European Medicines Agency (EMA) of the European Union announced that they started an investigation about the possible cancer risk of ARBs.

“This is the first time an association between ARBs and cancer development is suggested,” Dr. Sipahi continued. “While our findings are robust, they need to be replicated in other studies before they can be considered as definitive.”

The US Food and Drug Administration has not made any statement regarding this issue yet.

hematology oncology publications :: Q2 | 2010

July 8, 2010

Inhibition of Lck enhances glucocorticoid sensitivity and apoptosis in lymphoid cell lines and in chronic lymphocytic leukemia
Harr M, Caimi P, McColl K, Zhong F, Patel S, Barr P, Distelhorst C.
Cell Death Differ. 2010 Mar

Non-Hodgkin’s lymphoma in the elderly
Caimi PF, Barr PM, Berger NA, Lazarus HM.
Drugs Aging. 2010 Mar

Correlation between ZAP-70, phospho-ZAP-70, and phospho-Syk expression in leukemic cells from patients with CLL
Kaplan D, Meyerson HJ, Li X, Drasny C, Liu F, Costaldi M, Barr P, Lazarus HM.
Cytometry B Clin Cytom. 2010 Mar

Toxicity of sunitinib plus bevacizumab in renal cell carcinoma
Rini BI, Garcia JA, Cooney MM, Elson P, Tyler A, Beatty K, Bokar J, Ivy P, Chen HX, Dowlati A, Dreicer R.
J Clin Oncol. 2010 Jun

Variability of pulse oximetry measurement over 1 year in children with sickle cell disease depends on initial oxygen saturation measurement
Mullin JE, Cooper B, Seicean S, Strunk R, Rosen C, Redline S, Kemp J, DeBaun MR.
Pediatr Blood Cancer. 2010 Jul

Inhibition of Lck enhances glucocorticoid sensitivity and apoptosis in lymphoid cell lines and in chronic lymphocytic leukemia
Harr MW, Caimi P, McColl K, Zhong F, Patel S, Barr P, Distelhorst C.
Cell Death Differ. 2010 Mar

O-fucose modulates notch-controlled blood lineage commitment
Yan Q, Yao D, Wei LL, Huang Y, Myers J, Zhang L, Xin W, Shim J, Man Y, Petryniak B, Gerson S, Lowe JB, Zhou L.
Am J Pathol. 2010 Jun

Umbilical cord blood-selected CD133(+) cells exhibit vasculogenic functionality in vitro and in vivo
Finney MR, Fanning LR, Joseph ME, Goldberg JL, Greco NJ, Bhakta S, Winter DG, Forster M, Scheid PE, Sabe M, Pompili VJ, Laughlin MJ.
Cytotherapy. 2010

Correlation between ZAP-70, phospho-ZAP-70, and phospho-Syk expression in leukemic cells from patients with CLL
Kaplan D, Meyerson HJ, Li X, Drasny C, Liu F, Costaldi M, Barr P, Lazarus HM.
Cytometry B Clin Cytom. 2010 Mar

Astrocyte-restricted ablation of interleukin-17-induced Act1-mediated signaling ameliorates autoimmune encephalomyelitis
Kang Z, Altuntas CZ, Gulen MF, Liu C, Giltiay N, Qin H, Liu L, Qian W, Ransohoff RM, Bergmann C, Stohlman S, Tuohy VK, Li X.
Immunity. 2010 Mar

CXCR2-positive neutrophils are essential for cuprizone-induced demyelination: relevance to multiple sclerosis
Liu L, Belkadi A, Darnall L, Hu T, Drescher C, Cotleur AC, Padovani-Claudio D, He T, Choi K, Lane TE, Miller RH, Ransohoff RM.
Nat Neurosci. 2010 Mar

ARQ-197, an oral small-molecule inhibitor of c-Met for the treatment of solid tumors
Bagai R, Fan W, Ma PC.
IDrugs. 2010 Jun

A segregation analysis of Barrett’s esophagus and associated adenocarcinomas
Sun X, Elston R, Barnholtz-Sloan J, Falk G, Grady WM, Kinnard M, Mittal SK, Willis JE, Markowitz S, Brock W, Chak A.
Cancer Epidemiol Biomarkers Prev. 2010 Mar

Confirmation of Linkage to and Localization of Familial Colon Cancer Risk Haplotype on Chromosome 9q22
Gray-McGuire C, Guda K, Adrianto I, Lin CP, Natale L, Potter JD, Newcomb P, Poole EM, Ulrich CM, Lindor N, Goode EL, Fridley BL, Jenkins R, Le Marchand L, Casey G, Haile R, Hopper J, Jenkins M, Young J, Buchanan D, Gallinger S, Adams M, Lewis S, Willis J, Elston R, Markowitz SD, Wiesner GL.
Cancer Res. 2010 Jul

Malignant T cells in cutaneous T-cell lymphoma lesions contain decreased levels of the antiapoptotic protein Ku70
Ferenczi K, Ohtola J, Aubert P, Kessler M, Sugiyama H, Somani AK, Gilliam AC, Chen JZ, Yeh I, Matsuyama S, McCormick TS, Cooper KD.
Br J Dermatol. 2010 Apr

Securinine induces p73-dependent apoptosis preferentially in p53-deficient colon cancer cells
Rana S, Gupta K, Gomez J, Matsuyama S, Chakrabarti A, Agarwal ML, Agarwal A, Agarwal MK, Wald DN.
FASEB J. 2010 Jun

Factor XII stimulates ERK1/2 and Akt through uPAR, integrins, and the EGFR to initiate angiogenesis
LaRusch GA, Mahdi F, Shariat-Madar Z, Adams G, Sitrin RG, Zhang WM, McCrae KR, Schmaier AH.
Blood. 2010 Jun

Comorbidities, functional limitations, and geriatric syndromes in relation to treatment and survival patterns among elders with colorectal cancer
Koroukian SM, Xu F, Bakaki PM, Diaz-Insua M, Towe TP, Owusu C.
J Gerontol A Biol Sci Med Sci. 2010 Mar

Factor XII: what does it contribute to our understanding of the physiology and pathophysiology of hemostasis & thrombosis
Stavrou E, Schmaier AH.
Thromb Res. 2010 Mar

Cardiologists discover cancer risks in group of blood pressure medications

June 24, 2010

University Hospitals Case Medical Center cardiologists have uncovered new research showing an increased risk of cancer with a group of blood pressure medications known as angiotensin-receptor blockers (ARBs).

This class of drugs is used by millions of patients not only for high blood pressure but also for heart failure, cardiovascular risk reduction and diabetic kidney disease.

University Hospitals Harrington-McLaughlin Heart & Vascular Institute’s Drs. Ilke Sipahi, Daniel I. Simon and James C. Fang recently completed a meta-analysis of over 60,000 patients randomly assigned to take either an ARB or a control medication. Their findings are published online today at The Lancet Oncology.

The researchers found that patients randomized to ARBs has “significantly increased risk of new cancer” compared to control patients.

“We have found the risk of new cancers was increased with these medications by 8-11 percent,” said Dr. Ilke Sipahi, associate director of heart failure and transplantation and assistant professor at Case Western Reserve University School of Medicine. “Most importantly, risk of lung cancer was increased by 25 percent.”

However, the research did not establish any link between ARBs and other types of cancer such breast cancer.

“This is the first time an association between ARBs and cancer development is suggested,” Dr. Sipahi continued. “While our findings are robust, they need to be replicated in other studies before they can be considered as definitive.”

Before this study, there were no major safety concerns with ARBs except for their use in pregnancy and in patients with chronic kidney or blockages of kidney arteries. Interestingly, previous animal studies with ARBs have been negative for cancer development.

“In medicine, physicians must balance the benefits and risks of all drug and device therapies,” said Dr. Daniel Simon, director of the Harrington-McLaughlin Heart & Vascular Institute at University Hospitals Case Medical Center and professor at Case Western Reserve University School of Medicine. “We recommend that patients discuss the findings of this study with their physicians since ARBs are effective agents in the treatment of high blood pressure and heart failure. Meta-analyses are a powerful tool to look at low frequency safety signals, but require confirmation with other approaches, such as large national health and managed care registries.”

Prostate Cancer at CWRUmedicine

June 20, 2010

Worldwide, prostate cancer is one of the most common types of cancer found in men. Learning more about prostate cancer and treatment options can help you and your loved ones take an active part in making choices about care.

* Click here to read about new research conducted by the Division of Hematology Oncology at Case Western Reserve University.

The prostate is a chestnut-sized gland below the bladder, which contributes most of the fluid that combines with a man’s sperm to make semen.

Prostate cancer is the most common cancer other than skin cancer in American men and is the second leading cause of cancer death in men.

The American Cancer Society estimates that more than 234,000 men will be diagnosed with prostate cancer in 2006. Incidence rates for the disease are higher for African-American men than for white men.

Other Prostate Cancer Survivors ::

Harry Belafonte
Musician, actor and social activist Harry Belafonte

Robert De Niro
Actor Robert De Niro

Rudy Giuliani
Former New York City Mayor Rudy Giuliani

John Kerry
U.S. Senator & 2004 Presidential candidate John Kerry

Nelson Mandela
Former President of South Africa Nelson Mandela

Katie Couric visits Markowitz Lab

June 8, 2010

The day prior to Commencement, Katie Couric, CBS Evening News anchor and long time supporter of colon cancer research, visited Sanford “Sandy” Markowitz, MD, PhD, Ingalls Professor of Cancer Genetics, and Howard Hughes investigator, and his research team in his lab to gain a better understanding of the day-to-day research necessary for advancements in colon cancer.

Dr. Markowitz and his research team provided Couric a warm welcome, a tour of the lab, and hands-on experience and insight into the kind of research conducted inside the Markowitz lab. Couric and Dr. Markowitz have worked together for years in an effort to improve colon cancer screening and ultimately find a cure for the disease. Couric helped launch the National Colorectal Cancer Research Alliance, a foundation that raises awareness and funding for colon cancer research, after her late husband, Jay Monahan, succumbed to the disease in 1998.

Joseph Baar selected as Komen Pink Tie Guy 2010

May 25, 2010

Congratulations to Dr Joseph Baar on being selected as one of the 2010 Komen Northeast Ohio Pink Tie Guys. This special initiative was developed to get more men involved in the breast cancer movement. Men are often the people supporting breast cancer survivors through diagnosis, treatment and beyond. In addition, over 2000 men are diagnosed with breast cancer in the United States each year.

The eight prominent businessmen and celebrities are selected to be Pink Tie Guys represent the one in eight women who will be diagnosed with breast cancer in her lifetime. At Komen, we realize the smallest act can make a powerful impact. By simply wearing a pink tie, you may prompt a conversation that could literally save a life! Whether it be at a board meeting, social affair, or sporting event, this symbolic yet eye catching accessory may help others become proactive in learning the risk factors and how early detection is the best defense against breast cancer.

2010 Health Care Hero, Dr Joseph Baar, presented by Crain’s Cleveland Businesss

May 25, 2010

Congratulations on Joseph Baar on selection as a 2010 Health Care Hero presented by Crain’s Cleveland Business. We are pleased to recognize him as a Winner in the category of Advancements in Health Care.

The nomination submitted on Dr Baar’s behalf is a testament to the impact he has had on patients, colleagues and Northeast Ohio’s medical community.

Again, congratulations to Joseph Baar on his selection for this very special honor. As one of Northeast Ohio’s Health Care Heroes, he plays a vital role in the quality of our everyday lives and the economic future of the region.

Katie Couric Tours Case Western Reserve Research Lab

May 19, 2010

Katie Couric visited Sanford “Sandy” Markowitz, MD, PhD, professor and researcher of cancer and genetics, and his research team in his lab to gain a better understanding of the day-to-day research necessary for advancements in colon cancer.

The CBS Evening News with Katie Couric anchor and managing editor received a warm welcome from the researchers, who provided Couric with hands-on training. They also informed her of the various research projects being conducted in the Markowitz lab at Case Western Reserve University Department of Medicine.

The touching visit brought together Couric and Markowitz, who have been working together for years to improve colon cancer screening, and ultimately the disease. Couric’s late husband, Jay Monahan, succumbed to the disease in 1998.

Couric went on to help co-found The Entertainment Industry Foundation’s National Colorectal Cancer Research Alliance, which has raised awareness and funding for colon cancer research.

Learn more at CWRUmedicine.org